The FDA says it can't conclude that Novartis' (NVS) multiple sclerosis drug Gilenya was...

|About: Novartis AG (NVS)|By:, SA News Editor

The FDA says it can't conclude that Novartis' (NVS) multiple sclerosis drug Gilenya was connected to the unexplained deaths of patients, although the agency is still worried about the cardiovascular effects of the treatment following the first dose.